R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
Events Partner Content Welcome to 1st Rare & Genetic Neurodegenerative Drug Dev... Developing R&G neurodegenerative therapies
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
